

**Supplementary Table 1** Baseline demographic and disease characteristics of the study population

Characteristics	Study population n=44	GLM+MTX n=21	PLB+MTX n=23
Age at beginning of symptoms, median (IQR)	36.9 (15.3)	35.5(13.3)	37.3 (21.3)
<b>Patients' and physicians' reported outcomes</b>			
PGA for arthritis and psoriasis activity (0-100mm), median (IQR)	51.5 (35)	49(24)	60(39.5)
PGA for arthritis activity (0-100mm), median (IQR)	51 (28.3)	44 (24)	58 (33)
PGA for psoriasis activity (0-100mm), median (IQR)	32 (49.3)	30 (42)	40 (47.5)
PhGA for arthritis and psoriasis activity (0-100mm), median (IQR)	56(21.3)	50(20)	60 (20)
PhGA for arthritis activity (0-100mm), median (IQR)	50 (20)	50 (17.5)	50 (25)
PhGA for psoriasis activity (0-100mm), median (IQR)	30.5 (30)	30 (42.5)	40 (30)
<b>Health-related quality of life</b>			
Role physical	25 (100)	25 (100)	0 (100)
Bodily pain	41 (30)	51 (11)	41 (30)
SF 36, General health	40 (23.3)	40 (20)	40 (26)
median (IQR) Vitality	50(20)	50(20)	45 (17.5)
Social functioning	68.8 (40.6)	62.5(37.5)	75 (43.8)
Role emotional	66.7(100)	66.7(100)	100(83.3)
Mental health	64 (32)	64(32)	64(30)
<b>Laboratory inflammatory markers</b>			
Erythrocyte sedimentation rate (mm/1 <sup>st</sup> h), median (IQR)	24(24.8)	20(20)	26(25.5)
C reactive protein (mg/L), median (IQR)	5.3(11.4)	4.3(9.8)	7.7(13.3)

IQR: interquartile range; n: number; PGA: patient global assessment; PhGA: physician global assessment; SF: Short Form.